How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
50
AZN Quote, Financials, Valuation and Earnings
Last price:
$66.53
Seasonality move
:
1.27%
Day range:
$65.86 - $66.67
52-week range:
$60.47 - $87.68
Dividend yield:
2.23%
P/E ratio:
31.90x
P/S ratio:
4.06x
P/B ratio:
5.07x
Volume:
3.3M
Avg. volume:
6M
1-year change:
0.03%
Market cap:
$206.3B
Revenue:
$45.8B
EPS (TTM):
$2.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$13.1B | $1.03 | 17.56% | 255.34% | -- |
|
AMGN
Amgen
|
$8.5B | $5.11 | 8.07% | 254.55% | $322.43 |
|
GSK
GSK PLC
|
$10.4B | $1.16 | -1.61% | 107.8% | $42.93 |
|
JNJ
Johnson & Johnson
|
$22.2B | $2.21 | 4.95% | 21.99% | $172.53 |
|
MRNA
Moderna
|
$1.2B | -$1.94 | -63.53% | -79.68% | $127.09 |
|
SNY
Sanofi SA
|
$13.7B | $1.38 | -9.77% | 26.36% | $63.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$66.52 | -- | $206.3B | 31.90x | $0.50 | 2.23% | 4.06x |
|
AMGN
Amgen
|
$263.18 | $322.43 | $141.5B | 33.70x | $2.25 | 3.42% | 4.36x |
|
GSK
GSK PLC
|
$34.12 | $42.93 | $69.6B | 22.18x | $0.39 | 4.58% | 1.77x |
|
JNJ
Johnson & Johnson
|
$145.58 | $172.53 | $350.5B | 24.06x | $1.24 | 3.34% | 4.03x |
|
MRNA
Moderna
|
$40.43 | $127.09 | $15.6B | -- | $0.00 | 0% | 3.09x |
|
SNY
Sanofi SA
|
$48.29 | $63.06 | $121.1B | 24.47x | $2.04 | 8.15% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
42.54% | -0.572 | 12.47% | 0.71x |
|
AMGN
Amgen
|
88.92% | -0.086 | 34.87% | 0.80x |
|
GSK
GSK PLC
|
53.41% | 0.747 | 26% | 0.52x |
|
JNJ
Johnson & Johnson
|
33.76% | 0.599 | 9.16% | 0.70x |
|
MRNA
Moderna
|
-- | 0.826 | -- | 3.95x |
|
SNY
Sanofi SA
|
23.02% | -0.094 | -- | 0.52x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AZN
AstraZeneca PLC
|
$10.5B | $2.1B | 9.41% | 16.72% | 16.85% | $2B |
|
AMGN
Amgen
|
$5.2B | $2B | 6.14% | 65.35% | 45.6% | $3.3B |
|
GSK
GSK PLC
|
$7.3B | $245.9M | 8.08% | 18.89% | 2.75% | $1.7B |
|
JNJ
Johnson & Johnson
|
$15.5B | $5.3B | 14.07% | 20.88% | 15.71% | $5.7B |
|
MRNA
Moderna
|
$1.3B | -$70M | -17.44% | -17.44% | 1.46% | -$1.7B |
|
SNY
Sanofi SA
|
$11.1B | $4.5B | 4.56% | 5.8% | 26.62% | -$498.5M |
AstraZeneca PLC vs. Competitors
-
Which has Higher Returns AZN or AMGN?
Amgen has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 33.28%. AstraZeneca PLC's return on equity of 16.72% beat Amgen's return on equity of 65.35%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B AMGNAmgen61.07% $5.22 $67.9B -
What do Analysts Say About AZN or AMGN?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.31%. On the other hand Amgen has an analysts' consensus of $322.43 which suggests that it could grow by 22.51%. Given that AstraZeneca PLC has higher upside potential than Amgen, analysts believe AstraZeneca PLC is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 AMGNAmgen10 15 2 -
Is AZN or AMGN More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Amgen has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.307%.
-
Which is a Better Dividend Stock AZN or AMGN?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.23%. Amgen offers a yield of 3.42% to investors and pays a quarterly dividend of $2.25 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Amgen pays out 67.83% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or AMGN?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Amgen quarterly revenues of $8.5B. AstraZeneca PLC's net income of $1.4B is lower than Amgen's net income of $2.8B. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.90x while Amgen's PE ratio is 33.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.06x versus 4.36x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.06x 31.90x $13.6B $1.4B AMGNAmgen4.36x 33.70x $8.5B $2.8B
-
Which has Higher Returns AZN or GSK?
GSK PLC has a net margin of 10.54% compared to AstraZeneca PLC's net margin of -0.72%. AstraZeneca PLC's return on equity of 16.72% beat GSK PLC's return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B GSKGSK PLC70.08% -$0.04 $39.5B -
What do Analysts Say About AZN or GSK?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.31%. On the other hand GSK PLC has an analysts' consensus of $42.93 which suggests that it could grow by 32.11%. Given that AstraZeneca PLC has higher upside potential than GSK PLC, analysts believe AstraZeneca PLC is more attractive than GSK PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 GSKGSK PLC2 4 0 -
Is AZN or GSK More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.349%.
-
Which is a Better Dividend Stock AZN or GSK?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.23%. GSK PLC offers a yield of 4.58% to investors and pays a quarterly dividend of $0.39 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. GSK PLC pays out 45.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or GSK?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $10.4B. AstraZeneca PLC's net income of $1.4B is higher than GSK PLC's net income of -$75.5M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.90x while GSK PLC's PE ratio is 22.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.06x versus 1.77x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.06x 31.90x $13.6B $1.4B GSKGSK PLC1.77x 22.18x $10.4B -$75.5M
-
Which has Higher Returns AZN or JNJ?
Johnson & Johnson has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 11.99%. AstraZeneca PLC's return on equity of 16.72% beat Johnson & Johnson's return on equity of 20.88%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B JNJJohnson & Johnson69.01% $1.11 $105.9B -
What do Analysts Say About AZN or JNJ?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.31%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 19.71%. Given that AstraZeneca PLC has higher upside potential than Johnson & Johnson, analysts believe AstraZeneca PLC is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 JNJJohnson & Johnson8 13 0 -
Is AZN or JNJ More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.
-
Which is a Better Dividend Stock AZN or JNJ?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.23%. Johnson & Johnson offers a yield of 3.34% to investors and pays a quarterly dividend of $1.24 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or JNJ?
AstraZeneca PLC quarterly revenues are $13.6B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. AstraZeneca PLC's net income of $1.4B is lower than Johnson & Johnson's net income of $2.7B. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.90x while Johnson & Johnson's PE ratio is 24.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.06x versus 4.03x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.06x 31.90x $13.6B $1.4B JNJJohnson & Johnson4.03x 24.06x $22.5B $2.7B
-
Which has Higher Returns AZN or MRNA?
Moderna has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 0.7%. AstraZeneca PLC's return on equity of 16.72% beat Moderna's return on equity of -17.44%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B MRNAModerna72.29% $0.03 $11.9B -
What do Analysts Say About AZN or MRNA?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.31%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 83.5%. Given that Moderna has higher upside potential than AstraZeneca PLC, analysts believe Moderna is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 MRNAModerna7 12 1 -
Is AZN or MRNA More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.
-
Which is a Better Dividend Stock AZN or MRNA?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.23%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. AstraZeneca PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or MRNA?
AstraZeneca PLC quarterly revenues are $13.6B, which are larger than Moderna quarterly revenues of $1.9B. AstraZeneca PLC's net income of $1.4B is higher than Moderna's net income of $13M. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.90x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.06x versus 3.09x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.06x 31.90x $13.6B $1.4B MRNAModerna3.09x -- $1.9B $13M
-
Which has Higher Returns AZN or SNY?
Sanofi SA has a net margin of 10.54% compared to AstraZeneca PLC's net margin of 19.88%. AstraZeneca PLC's return on equity of 16.72% beat Sanofi SA's return on equity of 5.8%.
Company Gross Margin Earnings Per Share Invested Capital AZNAstraZeneca PLC77.29% $0.46 $70.9B SNYSanofi SA71.15% $1.24 $101.5B -
What do Analysts Say About AZN or SNY?
AstraZeneca PLC has a consensus price target of --, signalling upside risk potential of 32.31%. On the other hand Sanofi SA has an analysts' consensus of $63.06 which suggests that it could grow by 30.59%. Given that AstraZeneca PLC has higher upside potential than Sanofi SA, analysts believe AstraZeneca PLC is more attractive than Sanofi SA.
Company Buy Ratings Hold Ratings Sell Ratings AZNAstraZeneca PLC7 2 0 SNYSanofi SA5 1 0 -
Is AZN or SNY More Risky?
AstraZeneca PLC has a beta of 0.451, which suggesting that the stock is 54.86% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.585, suggesting its less volatile than the S&P 500 by 41.492%.
-
Which is a Better Dividend Stock AZN or SNY?
AstraZeneca PLC has a quarterly dividend of $0.50 per share corresponding to a yield of 2.23%. Sanofi SA offers a yield of 8.15% to investors and pays a quarterly dividend of $2.04 per share. AstraZeneca PLC pays 75.25% of its earnings as a dividend. Sanofi SA pays out 82.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AZN or SNY?
AstraZeneca PLC quarterly revenues are $13.6B, which are smaller than Sanofi SA quarterly revenues of $15.6B. AstraZeneca PLC's net income of $1.4B is lower than Sanofi SA's net income of $3.1B. Notably, AstraZeneca PLC's price-to-earnings ratio is 31.90x while Sanofi SA's PE ratio is 24.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AstraZeneca PLC is 4.06x versus 2.28x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AZNAstraZeneca PLC4.06x 31.90x $13.6B $1.4B SNYSanofi SA2.28x 24.47x $15.6B $3.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 49.62% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is up 10.88% over the past day.
